Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab

Infant cynomolgus monkeys exposed to denosumab in utero exhibit an osteoclast-poor osteopetrotic-like skeletal phenotype at birth and in the early postnatal period

(2014) Rogely W. Boyce et al.   BONE

Inhibition of Cathepsin K Increases Modeling-Based Bone Formation, and Improves Cortical Dimension and Strength in Adult Ovariectomized Monkeys

(2014) Brenda L Pennypacker et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Differing effects of denosumab and alendronate on cortical and trabecular bone

(2013) Roger M. Zebaze et al.   BONE

Annual intravenous zoledronic acid for three years increased cancellous bone matrix mineralization beyond normal values in the HORIZON biopsy cohort

(2012) Barbara M Misof et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody

(2011) Paul J. Kostenuik et al.   BONE

Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys

(2011) Michael S. Ominsky et al.   BONE

Bone turnover markers in peripheral blood and marrow plasma reflect trabecular bone loss but not endocortical expansion in aging mice

(2011) Mohammad Shahnazari et al.   BONE

Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid

(2010) Sonja Gamsjaeger et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Tumor necrosis factor α and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis

(2009) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparison of Effects of the Bisphosphonate Alendronate Versus the RANKL Inhibitor Denosumab on Murine Fracture Healing

(2008) Louis C Gerstenfeld et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Spectroscopic markers of bone quality in alendronate-treated postmenopausal women

(2008) A. L. Boskey et al.   OSTEOPOROSIS INTERNATIONAL